These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 27402056

  • 1. Complement inhibition in C3 glomerulopathy.
    Nester CM, Smith RJ.
    Semin Immunol; 2016 Jun; 28(3):241-9. PubMed ID: 27402056
    [Abstract] [Full Text] [Related]

  • 2. C3 glomerulopathy and current dilemmas.
    Ito N, Ohashi R, Nagata M.
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [Abstract] [Full Text] [Related]

  • 3. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.
    Diagn Pathol; 2016 Oct 07; 11(1):94. PubMed ID: 27717365
    [Abstract] [Full Text] [Related]

  • 4. C3 Glomerulopathy: Pathogenesis and Treatment.
    Ahmad SB, Bomback AS.
    Adv Chronic Kidney Dis; 2020 Mar 07; 27(2):104-110. PubMed ID: 32553242
    [Abstract] [Full Text] [Related]

  • 5. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M, Emma F.
    Semin Thromb Hemost; 2014 Jun 07; 40(4):472-7. PubMed ID: 24799307
    [Abstract] [Full Text] [Related]

  • 6. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
    Xiao X, Pickering MC, Smith RJ.
    Semin Thromb Hemost; 2014 Jun 07; 40(4):465-71. PubMed ID: 24799308
    [Abstract] [Full Text] [Related]

  • 7. C3 Glomerulopathy.
    Riedl M, Thorner P, Licht C.
    Pediatr Nephrol; 2017 Jan 07; 32(1):43-57. PubMed ID: 27056062
    [Abstract] [Full Text] [Related]

  • 8. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J, Berenberg-Goßler L, Wu K, Beringer O, Kropp F, Müller D, Thumfart J.
    Pediatr Nephrol; 2018 Dec 07; 33(12):2289-2298. PubMed ID: 30238151
    [Abstract] [Full Text] [Related]

  • 9. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
    Al-Ghaithi B, Chanchlani R, Riedl M, Thorner P, Licht C.
    Pediatr Nephrol; 2016 Nov 07; 31(11):2079-86. PubMed ID: 27008643
    [Abstract] [Full Text] [Related]

  • 10. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
    Hawfield A, Iskandar SS, Smith RJ.
    Am J Kidney Dis; 2013 May 07; 61(5):828-31. PubMed ID: 23391537
    [Abstract] [Full Text] [Related]

  • 11. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
    Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB.
    Kidney Int; 2018 Apr 07; 93(4):977-985. PubMed ID: 29310824
    [Abstract] [Full Text] [Related]

  • 12. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
    Zhang Y, Shao D, Ricklin D, Hilkin BM, Nester CM, Lambris JD, Smith RJ.
    Immunobiology; 2015 Aug 07; 220(8):993-8. PubMed ID: 25982307
    [Abstract] [Full Text] [Related]

  • 13. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS, Foster KW, Westphal SG.
    Clin Nephrol; 2020 Jan 07; 93(1):51-56. PubMed ID: 31661064
    [Abstract] [Full Text] [Related]

  • 14. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
    Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS.
    Am J Kidney Dis; 2019 Mar 07; 73(3):316-323. PubMed ID: 30413277
    [Abstract] [Full Text] [Related]

  • 15. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC.
    Kidney Int; 2017 Jun 07; 91(6):1386-1397. PubMed ID: 28139294
    [Abstract] [Full Text] [Related]

  • 16. [Membranoproliferative glomerulonephritis and C3 glomerulopathy].
    Hohenstein B, Amann K, Menne J.
    Internist (Berl); 2019 May 07; 60(5):458-467. PubMed ID: 30859280
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathological features of C3 glomerulopathy in children: a single-center experience.
    Drake KA, Ellington N, Gattineni J, Torrealba JR, Hendricks AR.
    Pediatr Nephrol; 2020 Jan 07; 35(1):153-162. PubMed ID: 31667615
    [Abstract] [Full Text] [Related]

  • 18. Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies.
    Lafayette RA, Charu V.
    Adv Ther; 2023 Dec 07; 40(12):5557-5566. PubMed ID: 37751024
    [Abstract] [Full Text] [Related]

  • 19. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ.
    Clin J Am Soc Nephrol; 2014 Nov 07; 9(11):1876-82. PubMed ID: 25341722
    [Abstract] [Full Text] [Related]

  • 20. C3 glomerulonephritis with a severe crescentic phenotype.
    Ravindran A, Fervenza FC, Smith RJH, Sethi S.
    Pediatr Nephrol; 2017 Sep 07; 32(9):1625-1633. PubMed ID: 28593446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.